Eli Lilly And Co (NYSE:LLY) agreed to acquire POINT Biopharma Global Inc (NASDAQ:PNT) at $12.50 per share in cash, an aggregate of approximately $1.4 billion.
POINT Biopharma is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for cancer.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased